Company details contemplated transaction structure designed to preserve shareholder value and enable future dividend distributions from core technologiesRA'ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outl ...

Core Insights - BioMark Diagnostics has completed a strategic laboratory equipment leasing agreement that significantly doubles its testing capacity, positioning the company for the commercial launch of its lung cancer assay [1][2] - The expansion is aimed at meeting the increasing global demand for non-invasive liquid biopsy diagnostics and supports the rollout of multiple new assays [2][3] - The upgraded laboratory will facilitate ongoing clinical research collaborations and streamline regulatory filings, enhancing BioMark's ability to enter international markets [3][4] Company Overview - BioMark Diagnostics is a leading developer of liquid biopsy tests for early cancer detection, utilizing metabolomics and machine learning algorithms to improve patient outcomes [5] - The company's technology allows for cancer-associated biomarker detection through a simple blood draw, which can also be used for treatment response measurement and monitoring of cancer survivors [5] Strategic Goals - The enhanced laboratory capacity reflects BioMark's commitment to clinical excellence and innovation, serving as a pivotal engine for commercialization and revenue generation [3][4] - The company aims to scale its AI-enhanced assays and foster collaborations across the cancer care spectrum, positioning itself advantageously within the diagnostic arena [4]